Bayer’s Xarelto Blood Thinner Matched Warfarin in Japanese Safety Study
Bayer AG (BAYN)’s Xarelto blood-thinner didn’t raise the risk of bleeding for irregular-heartbeat patients in a Japanese study comparing the medicine with warfarin, the former standard of care, the Leverkusen, Germany- based company said today.
The results confirmed those of the global Rocket study, Bayer said. The German drug and chemicals maker said in April it requested Japanese approval for Xarelto for irregular-heartbeat patients.
To contact the reporter on this story: Naomi Kresge in Zurich at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.